Logo image of LSTA

LISATA THERAPEUTICS INC (LSTA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:LSTA - US1280583022 - Common Stock

2.06 USD
-0.05 (-2.37%)
Last: 1/8/2026, 8:00:01 PM
Fundamental Rating

2

Taking everything into account, LSTA scores 2 out of 10 in our fundamental rating. LSTA was compared to 530 industry peers in the Biotechnology industry. While LSTA seems to be doing ok healthwise, there are quite some concerns on its profitability. LSTA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

LSTA had negative earnings in the past year.
LSTA had a negative operating cash flow in the past year.
LSTA had negative earnings in each of the past 5 years.
LSTA had a negative operating cash flow in each of the past 5 years.
LSTA Yearly Net Income VS EBIT VS OCF VS FCFLSTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

LSTA has a worse Return On Assets (-83.84%) than 69.43% of its industry peers.
With a Return On Equity value of -105.00%, LSTA perfoms like the industry average, outperforming 44.72% of the companies in the same industry.
Industry RankSector Rank
ROA -83.84%
ROE -105%
ROIC N/A
ROA(3y)-56.5%
ROA(5y)-44.09%
ROE(3y)-64.1%
ROE(5y)-49.43%
ROIC(3y)N/A
ROIC(5y)N/A
LSTA Yearly ROA, ROE, ROICLSTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LSTA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LSTA Yearly Profit, Operating, Gross MarginsLSTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

More info and screens

6

2. Health

2.1 Basic Checks

LSTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
LSTA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for LSTA has been increased compared to 5 years ago.
There is no outstanding debt for LSTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LSTA Yearly Shares OutstandingLSTA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
LSTA Yearly Total Debt VS Total AssetsLSTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -35.65, we must say that LSTA is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -35.65, LSTA is not doing good in the industry: 89.06% of the companies in the same industry are doing better.
There is no outstanding debt for LSTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -35.65
ROIC/WACCN/A
WACC8.79%
LSTA Yearly LT Debt VS Equity VS FCFLSTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 4.72 indicates that LSTA has no problem at all paying its short term obligations.
LSTA's Current ratio of 4.72 is in line compared to the rest of the industry. LSTA outperforms 54.91% of its industry peers.
A Quick Ratio of 4.72 indicates that LSTA has no problem at all paying its short term obligations.
The Quick ratio of LSTA (4.72) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.72
Quick Ratio 4.72
LSTA Yearly Current Assets VS Current LiabilitesLSTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 15.14% over the past year.
EPS 1Y (TTM)15.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 12.18% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y9.05%
EPS Next 2Y26.17%
EPS Next 3Y19.8%
EPS Next 5Y12.18%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LSTA Yearly Revenue VS EstimatesLSTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2022 2024 2025 2027 2028 2029 2030 2031 50M 100M 150M 200M
LSTA Yearly EPS VS EstimatesLSTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -50 -100 -150 -200

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LSTA. In the last year negative earnings were reported.
Also next year LSTA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LSTA Price Earnings VS Forward Price EarningsLSTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LSTA Per share dataLSTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

LSTA's earnings are expected to grow with 19.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.17%
EPS Next 3Y19.8%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LSTA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

LISATA THERAPEUTICS INC

NASDAQ:LSTA (1/8/2026, 8:00:01 PM)

2.06

-0.05 (-2.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners8.38%
Inst Owner Change0%
Ins Owners7.17%
Ins Owner Change0%
Market Cap18.17M
Revenue(TTM)1.07M
Net Income(TTM)-18.24M
Analysts82.22
Price Target13.26 (543.69%)
Short Float %0.22%
Short Ratio0.21
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.38%
Min EPS beat(2)10.21%
Max EPS beat(2)18.55%
EPS beat(4)3
Avg EPS beat(4)14.02%
Min EPS beat(4)-1.74%
Max EPS beat(4)29.05%
EPS beat(8)7
Avg EPS beat(8)17.46%
EPS beat(12)11
Avg EPS beat(12)19.51%
EPS beat(16)13
Avg EPS beat(16)-30.07%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-37.1%
EPS NQ rev (1m)0%
EPS NQ rev (3m)17.74%
EPS NY rev (1m)0%
EPS NY rev (3m)3.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.98
P/FCF N/A
P/OCF N/A
P/B 1.05
P/tB 1.05
EV/EBITDA N/A
EPS(TTM)-2.13
EYN/A
EPS(NY)-0.98
Fwd EYN/A
FCF(TTM)-1.96
FCFYN/A
OCF(TTM)-1.95
OCFYN/A
SpS0.12
BVpS1.97
TBVpS1.95
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -83.84%
ROE -105%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.5%
ROA(5y)-44.09%
ROE(3y)-64.1%
ROE(5y)-49.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.72
Quick Ratio 4.72
Altman-Z -35.65
F-Score4
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.95%
EPS Next Y9.05%
EPS Next 2Y26.17%
EPS Next 3Y19.8%
EPS Next 5Y12.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y14.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.04%
EBIT Next 3Y-10.73%
EBIT Next 5Y-1.14%
FCF growth 1Y23.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.19%
OCF growth 3YN/A
OCF growth 5YN/A

LISATA THERAPEUTICS INC / LSTA FAQ

What is the ChartMill fundamental rating of LISATA THERAPEUTICS INC (LSTA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to LSTA.


What is the valuation status for LSTA stock?

ChartMill assigns a valuation rating of 0 / 10 to LISATA THERAPEUTICS INC (LSTA). This can be considered as Overvalued.


How profitable is LISATA THERAPEUTICS INC (LSTA) stock?

LISATA THERAPEUTICS INC (LSTA) has a profitability rating of 0 / 10.


How financially healthy is LISATA THERAPEUTICS INC?

The financial health rating of LISATA THERAPEUTICS INC (LSTA) is 6 / 10.


What is the earnings growth outlook for LISATA THERAPEUTICS INC?

The Earnings per Share (EPS) of LISATA THERAPEUTICS INC (LSTA) is expected to grow by 9.05% in the next year.